**ACG Presenter Disclosure Declaration**

*Please read the Abstract Disclosure Policy and answer the questions that follow.*

*Any individual who refuses to disclose financial relationships will be disqualified from presenting.*

|  |
| --- |
| **ACG POLICIES FOR DISCLOSURE AND PARTICIPATION** |
| The American College of Gastroenterology (ACG) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. ACG, as an ACCME accredited provider, ensures balance, independence, objectivity, and scientific rigor in all of its directly and jointly provided education activities. **All who are in a position to control the content of an accredited activity are required to disclose to ACG all financial relationships in any amount occurring in the past 24 months with ineligible companies** (see definitions below). The ACCME Standards for Integrity and Independence require that ACG disqualify individuals who refuse to provide this information from involvement in the planning and implementation of accredited continuing education. For all those in control of CME content, ACG will identify and mitigate relevant financial relationships prior to the individuals assuming their roles, and will disclose all relevant financial relationships to the learners prior to the beginning of an education activity.  The Accreditation Council for Continuing Medical Education (ACCME) has released new Standards for Integrity and Independence in Accredited Continuing Education. Please be certain to thoroughly read the definitions and statements below before completing this disclosure task, as ACG has recently updated this form to reflect these new ACCME Standards.  **CONTENT VALIDATION**  Under policies established by the ACCME, ACG is required to confirm the following content validation statements with respect to clinical medicine information included in the educational content presented at its meetings. Authors/presenters are requested to review these statements, and required to notify ACG if they expect that any content of their presentations might be perceived as contrary to the following statements:   * All recommendations for patient care in accredited continuing education must be based on current science, evidence, and clinical reasoning, while giving a fair and balanced view of diagnostic and therapeutic options. * All scientific research referred to, reported, or used in accredited education in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, analysis, and interpretation. * Although accredited continuing education is an appropriate place to discuss, debate, and explore new and evolving topics, these areas need to be clearly identified as such within the program and individual presentations. It is the responsibility of accredited providers to facilitate engagement with these topics without advocating for, or promoting, practices that are not, or not yet, adequately based on current science, evidence, and clinical reasoning. * Content cannot be included in accredited education if it advocates for unscientific approaches to diagnosis or therapy, or if the education promotes recommendations, treatment, or manners of practicing healthcare that are determined to have risks or dangers that outweigh the benefits or are known to be ineffective in the treatment of patients.   **OFF-LABEL USAGE POLICY**  If any unapproved or off-label use of a product is to be referenced in a CME program presentation, the author/presenter is required to disclose that the product is either investigational or it is not labeled for the usage being discussed.  **SAFEGUARDS AGAINST COMMERCIAL BIAS**  CME must give a balanced view of therapeutic options. Use of generic names will contribute to this impartiality. Should it be necessary to use a trade name, trade names from several companies should be used where available, not just trade names from a single company. Educational materials that are part of this CME activity, such as slides, abstracts and handouts, cannot contain any advertising, corporate logo, trade name or a product-group message of an ACCME-defined ineligible company.  **DISQUALIFICATION**  Any author/presenter who either refuses to disclose financial relationships, or who violates the policy related to unapproved or off-label usage, shall be disqualified from participation in this CME activity and may be precluded from consideration of future presentations at ACG CME events/programs. |

|  |  |  |
| --- | --- | --- |
| **Title of CME Activity:** ACG 2023 Annual Scientific Meeting | | **Dates:** October 20 – 25, 2023 |
| **Type of Presentation:** Late-Breaking Abstract | | **Location:** Vancouver Convention Centre, Vancouver, BC, Canada |
| *Please print Title, Presenter Name, and Email clearly* | | |
| **Title of Abstract:** |  | |
| **Presenter Name:** |  | |
| **Presenter’s Email:** |  | |
| **In accordance with ACG and ACCME guidelines, the presenting author may not be an employee of an ACCME-defined ineligible company\*** | | |

|  |
| --- |
| **I. DISCLOSURE OF FINANCIAL RELATIONSHIPS** |
| Check one of the following statements after reviewing the definitions below: |
| \_\_\_\_ Neither I nor my co-authors have any financial relationships\* with an ACCME-defined ineligible company\* (see definition below) within the past 24 months.  \_\_\_\_ I and/or my co-authors have a financial relationship\* with an ACCME-defined ineligible company\* (see definition below) within the past 24 months. **(You must provide the information in the box below FOR ALL AUTHORS.)** |

|  |
| --- |
| For each financial relationship, enter the name of the ineligible company and the nature of the financial relationship(s). There is no minimum financial threshold; we ask that you disclose all financial relationships, regardless of the amount, with ineligible companies. You should disclose all financial relationships regardless of the potential relevance of each relationship to the education.  You must (1) list the ineligible company(s)\* and (2) describe the nature of the financial relationship(s)\* for **EACH** author. Indicate “nothing to disclose” for authors with no financial relationships\*. [Relationships: Advisor or Review Panel Member; Advisory Committee/Board Member; Consultant; Employee; Grant/Research Support; Independent Contractor; Intellectual Property/Patents; Owner/Ownership Interest; Royalties; Speakers Bureau; Stock Options; Stock-privately held company; Stock-publicly held company (excluding mutual/index funds); Other (please describe)].  **Example:**  **Dr. Smith – Consultant, Company A; Speakers Bureau, Company B**  **Dr. Jones - nothing to disclose** |
| **\*Ineligible Company** The ACCME defines an "ineligible company" (formerly known as a "commercial interest") as any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.  **\*Financial Relationships** Examples of financial relationships include employee, researcher, consultant, advisor, speaker, independent contractor (including contracted research), royalties or patent beneficiary, executive role, and ownership interest. Individual stocks and stock options should be disclosed; diversified mutual funds do not need to be disclosed. Research funding from ineligible companies should be disclosed by the principal or named investigator even if that individual’s institution receives the research grant and manages the funds.  **\*Relevant Financial Relationships** Financial relationships are relevant if the educational content an individual can control is related to the business lines or products of the ineligible company. |

|  |
| --- |
| **II. DISCLOSURE OF RELATIONSHIPS IN INDUSTRY-SUPPORTED RESEARCH SUBMITTED FOR ABSTRACT CONSIDERATION** |

|  |
| --- |
| **Initiated Research** |
| 1) Who initiated the research? |
| \_\_\_ Industry  \_\_\_ Investigator |

|  |
| --- |
| **Investigator Contribution** |
| 5) Did the investigator contribute patients to the study? |
| \_\_\_Yes  \_\_\_ No |

|  |
| --- |
| **FDA Approval** |
| 2) Reason for the research: was it for FDA approval or FDA treatment indication? |
| \_\_\_Yes  \_\_\_ No |

|  |
| --- |
| **Abstract Author** |
| 6) Who wrote the abstract? |
| \_\_\_Industry  \_\_\_ Investigator  \_\_\_ Other commercial entity |

|  |
| --- |
| **Study Results** |
| 7A) Are these the main results of the study? |
| \_\_\_ Yes  \_\_\_ No |

|  |
| --- |
| **Designed Study** |
| 3) Who designed the study? |
| \_\_\_ Industry  \_\_\_Investigator |

|  |
| --- |
| **Secondary Analyses** |
| 7B) If no, are these the results of secondary analyses? |
| \_\_\_Yes  \_\_\_ Not Applicable  \_\_\_No |

|  |
| --- |
| **Performed Analyses** |
| 4) Who performed the analyses? |
| \_\_\_ Industry  \_\_\_ Other commercial entity  \_\_\_Investigator |

|  |  |
| --- | --- |
| **Supported by Industry Grant** | |
| 8) Was this research supported by an industry grant? | |
| \_\_\_No  \_\_\_Yes | If yes, please specify which company/companies the grant is from. |

|  |
| --- |
| **Agreement** |
| **I certify that this information is complete and I accept responsibility for the accuracy of the information in response to the aforementioned questions.**  **Signature:** **\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ Date: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_**  \_\_\_ By checking this box you are signing on behalf of all authors. |

**Complete all sections and return all 3 pages via email no later than Thursday, August 15, 2023 to:** [**abstracts@gi.org**](mailto:abstracts@gi.org)